Drugs / Bone Healing Accelerant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04056429 | Jul 2026 → Sep 2028 | — | Carmell Therapeutics Corporation | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bone Healing Accelerant | “Bone Healing Accelerant (BHA) product” NCT04056429 ↗ |
| Known as | BHA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04056429 ↗ |
| Route | Other | “It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.” NCT04056429 ↗ |